CAR-T don Lupus Erythematosus na Tsari (SLE)

Ms.C majiyyaciya ce wadda aka yi nasarar yi wa SLE magani ta hanyar maganin CAR-T. Ga labarinta.

Bayanin Shari'a:

Ms. C, wata mace mai shekaru 32, ta shafe shekaru biyu tana fama da cutar lupus erythematosus (SLE). Duk da cewa an yi mata magani na gargajiya da dama, yanayinta bai daidaita ba. Ta sha fama da manyan alamu, ciki har da nephritis, ciwon gaɓɓai, da kuraje masu ɗorewa, waɗanda suka yi tasiri sosai ga ingancin rayuwarta.

Yanayin Kafin Jiyya:

An gano cutar SLE ta Ms. C da alamunta masu tsanani, ciki har da ciwon gaɓoɓi masu rauni, ciwon nephritis mai sake dawowa, da kuraje masu tsanani. Gwaje-gwajen dakin gwaje-gwaje sun nuna ƙaruwar ƙwayoyin rigakafi na DNA masu hana ƙwayoyin cuta biyu da kuma raguwar matakan C3 da C4, wanda ke nuna alamun cutar da ke aiki. Tare da ma'aunin ayyukan cutar Lupus Erythematosus Disease Activity Index (SLEDAI-2K) na 16, an ɗauki yanayin Ms. C a matsayin mai tsanani, kuma magungunan rage garkuwar jiki na yau da kullun sun gaza kawo sauƙi.

Shawarar Maganin CAR-T:

Ganin yadda take fama da rashin lafiya, an yi wa Ms. C gwajin asibiti don maganin ƙwayoyin CAR-T—wani magani mai sauyi da aka fara ƙirƙirawa don wasu cututtukan daji, amma yanzu ana bincikensa don cututtukan da ke ɗauke da garkuwar jiki kamar SLE. Maganin CAR-T yana aiki ta hanyar ƙirƙirar ƙwayoyin T na majiyyaci ta hanyar amfani da kwayoyin halitta don kai hari ga takamaiman ƙwayoyin rigakafi waɗanda ke taka muhimmiyar rawa a cikin tsarin cutar.

Tsarin Jiyya na CAR-T:

1. Zaɓin Marasa Lafiya: Ms. C mai tsanani da rashin iya jurewa SLE ta sanya ta zama wacce ta dace da maganin CAR-T.

2. Shiri: Kafin a ba wa Ms. C ƙwayoyin CAR-T, an yi mata tiyatar maganin chemotherapy, wani mataki na yau da kullun don rage adadin ƙwayoyin lymphocytes da ke jikinta da kuma shirya garkuwar jikinta don allurar CAR-T.

3. Injiniyan T-cell: An tattara ƙwayoyin T na Ms. C kuma an gyara su a cikin dakin gwaje-gwaje don bayyana masu karɓar antigen na chimeric (CAR) waɗanda ke nufin antigens na CD19 da BCMA. Waɗannan antigens galibi ana samun su a saman ƙwayoyin B, waɗanda ke taka muhimmiyar rawa a cikin rashin daidaituwar garkuwar jiki da ake gani a cikin SLE.

4. Jikowar Kwayoyin CAR-T: Bayan faɗaɗawa da gwajin inganci, an sake mayar da ƙwayoyin CAR-T da aka gyara cikin jikin Ms. C. Wannan jiko ya nuna farkon sabon babi a yaƙinta da lupus.

5. Kulawa da Marasa Lafiya a Cikin Gida: An kula da Ms. C sosai na tsawon kwanaki 25 bayan an yi mata allurar domin tabbatar da lafiyarta da ingancinta. Ma'aikatan lafiya sun sa ido sosai kan duk wata alama ta illa, kamar su cutar cytokine release syndrome (CRS), wani abu da aka saba gani ga maganin CAR-T.

Sakamakon Magani:

1. Amsar Na ɗan Gajere: Cikin makonni uku kacal da allurar, Ms. C ta sami ci gaba sosai a alamunta. Ciwon gaɓoɓinta da kumburinta sun ragu, kuma kurajen da ke damunta tsawon shekaru sun fara ɓacewa. Gwaje-gwajen dakin gwaje-gwaje sun kuma nuna cewa an kawar da ƙwayoyin B a cikin jininta yadda ya kamata, wanda ya tabbatar da cewa ƙwayoyin CAR-T sun yi nasarar kai hari ga sassan garkuwar jikinta da ke fama da rashin aiki.

2. Kimantawar Tsakiyar Lokaci (Watanni 3): A cikin watanni uku, aikin Ms. C na cutar ya kusan ƙarewa, inda sakamakon SLEDAI-2K ɗinta ya ragu daga 16 zuwa 2. Ciwon nephritis ɗinta, babban abin damuwa kafin magani, yanzu an shawo kansa, tare da raguwar furotin a cikin fitsari. Bugu da ƙari, matakan antibody na DNA ɗinta masu hana ƙwayoyin cuta sun ragu, kuma matakan C3 da C4 nata sun koma daidai, wanda ke nuna dawo da daidaiton garkuwar jiki.

3. Sakamako na Dogon Lokaci (Watanni 12): Shekara guda bayan shan maganin CAR-T, Ms. C ta ci gaba da samun sauƙi ba tare da magani ba, ba tare da wata alama ta sake dawowa daga SLE ba. Tsarin garkuwar jikinta ya farfaɗo a hankali, kuma yayin da ƙwayoyin B ɗinta suka sake bayyana, ba su nuna wani aiki na cutar ba. Baya ga fuskantar CRS mai sauƙi, Ms. C ba ta da wata mummunar illa a duk lokacin da ake yin maganin.

Ƙarin bayanai game da magani:

Maganin CAR-T ya nuna babban alhaki wajen magance cutar lupus erythematosus (SLE), musamman ga marasa lafiya da ke fama da cututtuka masu tsanani, waɗanda ba sa jure magani. Binciken da aka yi kwanan nan ya nuna ingancinsa, inda marasa lafiya da yawa ke fuskantar sassaucin magani na dogon lokaci.

A wani bincike da ya shafi marasa lafiya takwas, duk sun nuna cikakkiyar sassaucin kamuwa da cutar bayan sun sami maganin ƙwayoyin CAR-T wanda ke nufin ƙwayoyin B-19 masu kyau. Maganin ya haifar da raguwar waɗannan ƙwayoyin B, waɗanda ke da alhakin samar da ƙwayoyin rigakafi masu cutarwa a cikin SLE. Abu mai mahimmanci, ko da bayan sake farfaɗo da ƙwayoyin B, cutar ba ta dawo ba, kuma marasa lafiya sun sami damar kiyaye martanin rigakafi na yau da kullun ga alluran rigakafi. Wannan yana nuna yanayin dorewar tasirin maganin CAR-T akan tsarin garkuwar jiki, musamman wajen dakatar da hare-haren garkuwar jiki da ke da alaƙa da SLE.

Wani bincike da aka yi kan marasa lafiya sama da watanni 13 ya nuna cewa dukkan mahalarta sun sami raguwar ayyukan cutar sosai, kuma ba a ga ko da sake dawowa ba. Bugu da ƙari, an jure wa maganin sosai, tare da rage illa kamar su cytokine release syndrome (CRS) da ake iya jurewa.

Waɗannan sakamako masu kyau sun nuna cewa maganin CAR-T zai iya samar da mafita mai inganci da dogon lokaci ga marasa lafiya da ke fama da SLE mai tsauri, wanda hakan zai iya kawar da buƙatar magungunan rage garkuwar jiki na tsawon rai.